Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Recipharm AB, commonly referred to as Recipharm, is a leading provider of research and development services within the pharmaceutical industry. Headquartered in Sweden, the company operates across multiple regions, supporting clients globally with innovative R&D solutions. Founded in 2008, Recipharm has established a strong market presence through its focus on developing and manufacturing complex pharmaceutical products.
Specialising in formulation development, clinical trial materials, and manufacturing services, Recipharm’s offerings are distinguished by their commitment to quality and flexibility. The company’s expertise in customised solutions has earned it a notable position in the research and development services sector, making it a trusted partner for pharmaceutical companies seeking innovative drug development support.
+17 vs industry average
Recipharm’s score of 50 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has below-average carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
Recipharm, a Research and development services company headquartered in Sweden, reported total carbon emissions of approximately 208,000 tonnes CO2e in 2024. This figure includes about 22,773 tonnes CO2e from Scope 1 emissions, 1,600 tonnes CO2e from Scope 2 emissions, and 183,618 tonnes CO2e from Scope 3 emissions.
In 2023, the company's Scope 1 emissions were about 24,216 tonnes CO2e, Scope 2 emissions were approximately 3,193 tonnes CO2e, and Scope 3 emissions were around 179,203 tonnes CO2e. In 2022, Recipharm's Scope 1 emissions were approximately 24,667 tonnes CO2e, Scope 2 emissions were about 14,477 tonnes CO2e, and Scope 3 emissions were around 184,639 tonnes CO2e.
Recipharm has set ambitious climate commitments validated by the Science Based Targets initiative (SBTi). The company commits to reducing absolute Scope 1 and 2 GHG emissions by 42.1% by 2030 from a 2021 base year. Additionally, Recipharm aims to reduce absolute Scope 3 GHG emissions by 25.0% by 2030 from a 2021 base year, covering categories such as purchased goods and services, fuel and energy-related activities, and upstream transportation. The company also aims for Net Zero Scope 2 GHG emissions by 2030, Net Zero Scope 1 GHG emissions by 2040, and Net Zero Scope 3 GHG emissions by 2050. Recipharm also plans to increase its active annual sourcing of renewable electricity to 100% by 2030, from 93.5% in 2021.
2030
42.1% reduction in Scope 2
Recipharm commits to reduce absolute scope 2 GHG emissions 42.1% by 2030 from a 2021 base year.
2030
42.1% reduction in Scope 1
Recipharm commits to reduce absolute scope 1 GHG emissions 42.1% by 2030 from a 2021 base year.
2030
25% reduction in scope 3 total
Recipharm further commits to reduce absolute scope 3 GHG emissions 25.0% by 2030 from a 2021 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Recipharm’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more